Tiny trial hopes drug can ease liver damage in rare triple condition
Disease control
Completed
This completed phase 2 trial tested a drug called foscenvivint in just 5 people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function scores over 24 weeks. Because the study is very s…
Phase: PHASE2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC